Wire · opportunities
Highly anticipated cholesterol drug fails to prevent heart attacks, strokes
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 7 November 2026 · Fusion42 review
The experimental drug pelacarsen, designed to reduce high lipoprotein(a) levels, failed to reduce heart attacks, strokes, or cardiovascular deaths in a large clinical trial despite significantly lowering Lp(a). This outcome challenges assumptions about targeting Lp(a) for cardiovascular risk reduction and leaves open questions for future drug development.
This Wire brief sits within Fusion42's coverage of Health, and 4 sources have reported it between 7 Nov 2026 and 8 Nov 2026.
◆ ◆ The Wire takeaway
You face a setback if your healthtech targets genetic cholesterol risks with pelacarsen-like approaches. Now is the time to explore earlier intervention or alternate mechanisms as this failed trial resets expectations for Lp(a)-lowering drugs.
◆ Coverage
4 sources · first reported 7 Nov 2026 · latest 8 Nov 2026
◆ Related on Wire
◆ Topics